

9. a. Morabia, A. Pierre-Charles-Alexandre Louis and the Evaluation of Bloodletting. *J. R. Soc. Med.* **2006**, *99* (3), 158–160.  
b. Louis, P. C. A. *Recherches sur les Effets de la Saignée*; De Mignaret: Paris, 1835.
10. Greenwood, M.; Yule, G. U. The Statistics of Anti-typhoid and Anti-cholera Inoculations and the Interpretation of Such Statistics in General. *Proc. R. Soc. Med., Sect. Epidemiol. State Med.* **1915**, *8*, 113–194.
11. Ferguson, F. R.; Davey, A. F. C.; Topley, W. W. C. The Value of Mixed Vaccines in the Prevention of the Common Cold. *J. Hyg.* **1927**, *26*, 98–109.
12. Marshall, G.; Blacklock, J. W. S.; Cameron, C.; Capon, N. B.; Cruickshank, R.; Gaddum, J. H.; Heaf, F. R. G.; Hill, A. B.; Houghton, L. E.; Hoyle, J. C.; Raistrick, H.; Scadding, J. G.; Tytler, W. H.; Wilson, G. S.; Hart, P. D. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. *Br. Med. J.* **1948**, *2* (4582), 769–782.
13. Smith, L. J. Types of Clinical Trials 107–122. In *From Drug and Biological Development from Molecule to Product and beyond*; Evens, R. P., Ed.; Springer Science: New York, 2007.
14. Carlton, R. A. *Pharmaceutical Microscopy*, 213–246. Springer Science: New York, 2011.
15. a. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: An Extraordinary Example of Conformational Polymorphism. *Pharm. Res.* **2001**, *18* (6), 859–866.  
b. Morisette, S. L.; Soukasene, S.; Levinson, D.; Cima, M. J.; Almarsson, O. Elucidation of Crystal Form Diversity of the HIV Protease Inhibitor Ritonavir by High-throughput Crystallization. *Proc. Natl. Acad. Sci. U.S.A.* **2003**, *100* (5), 2180–2184.
16. Devillers, G. Exploring a Pharmaceutical Market Niche & Trends: Nasal Spray Drug Delivery. *Drug Delivery Technol.* **2003**, *3* (3), 1–4.
17. Tacconelli, E.; De Angelis, G.; Cataldo, M. A.; Pozzi, E.; Cauda, R. Does Antibiotic Exposure Increase the Risk of Methicillin-resistant *Staphylococcus aureus* (MRSA) Isolation? A Systematic Review and Meta-analysis. *J. Antimicrob. Chemother.* **2008**, *61* (1), 26–38.
18. Fleming, A. Penicillin. *Nobel Lecture December 11, 1945*. [http://www.nobelprize.org/nobel\\_prizes/medicine/laureates/1945/fleming-lecture.pdf](http://www.nobelprize.org/nobel_prizes/medicine/laureates/1945/fleming-lecture.pdf).
19. a. Tiwari, G.; Tiwari, R.; Sriwastawa, B.; Bhati, L.; Pandey, S.; Pandey, P.; Bannerjee, S. K. Drug Delivery Systems: An Updated Review. *Int. J. Pharm. Invest.* **2012**, *2* (1), 2–11.  
b. Hillery, A. M.; Lloyd, A. W.; Swarbrick, J. *Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists*; Taylor and Francis: New York, 2001.
20. Cady, R. K.; Wendt, J. K.; Kirchner, J. R.; Sargent, J. D.; Rothrock, J. F.; Skaggs, H., Jr. Treatment of Acute Migraine with Subcutaneous Sumatriptan. *JAMA* **1991**, *265* (21), 2831–2835.
21. Doggrell, S. A. Zoledronate Once-yearly Increases Bone Mineral Density - Implications for Osteoporosis. *Expert Opin. Pharmacother.* **2002**, *3* (7), 1007–1009.
22. Black, D. M.; Cummings, S. R.; Karpf, D. B.; Cauley, J. A.; Thompson, D. E.; Nevitt, M. C.; Bauer, D. C.; Genant, H. K.; Haskell, W. L.; Marcus, R.; Ott, S. M.; Torner, J. C.; Quandt, S. A.; Reiss, T. F.; Ensrud, K. E. Randomised Trial of Effect of Alendronate on Risk of Fracture in Women with Existing Vertebral Fractures. Fracture Intervention Trial Research Group. *Lancet* **1996**, *348* (9041), 1535–1541.
23. Recker, R. R.; Barger-Lux, J. Risedronate for Prevention and Treatment of Osteoporosis in Postmenopausal Women. *Expert Opin. Pharmacother.* **2005**, *6* (3), 465–477.
24. Bauss, F.; Schimmer, R. C. Ibandronate: the First Once-monthly Oral Bisphosphonate for Treatment of Postmenopausal Osteoporosis. *Ther. Clin. Risk Manage.* **2006**, *2* (1), 3–18.
25. a. Weintraub, A. Pfizer's Exubera Flop. *Businessweek* **October 18, 2007**.  
b. Heinemann, L. The Failure of Exubera: Are We Beating a Dead Horse? *J. Diabetes Sci. Technol.* **2008**, *2* (3), 518–529.